Autolus publishes corporate presentation on next-generation programmed T-cell therapies, led by AUCATZYL franchise expansion

Autolus highlighted AUCATZYL momentum, reporting 1H 2026 net product revenue of $71.9 million.

• FY 2026 net product revenue guidance was raised to $140 million-$150 million.
• Manufacturing success rate was reported above 90%, with no capacity constraints on product delivery.
• FELIX pivotal data cited a 77% remission rate (CR/CRi), 2% grade ≥3 CRS, 7% grade ≥3 ICANS, and median response of 42.6 months.
• Pipeline priorities include pivotal Phase 2 trials in lupus nephritis and pediatric ALL, with Phase 1 development in progressive multiple sclerosis.